Skadden advised Trimble, and Davis Polk advised the representatives of the several underwriters. Trimble Inc. announced an SEC-registered offering of $800 million aggregate principal amount of...
Trimble’s $800 Million Notes Offering
Stanley Black & Decker’s $750 Million Notes Offering
Skadden advised Stanley Black & Decker, and Davis Polk advised the joint book-running managers and representatives of the underwriters on the offering. Stanley Black & Decker,...
Ankura Consulting Group’s Acquisition of Chartwell Compliance
Davis Polk served as legal advisor to Ankura, and Squire Patton Boggs served as legal advisor to MVB Financial Corp. Ankura Consulting Group, LLC announced that it...
Eli Lilly’s $4 Billion Notes Offering
Kirkland & Ellis advised Eli Lilly, and Davis Polk advised the joint book-running managers for the offering. Eli Lilly and Company announced a registered offering of...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
CureVac’s $250 Million Common Shares Offering
NautaDutilh and Davis Polk advised CureVac on the offering, while Latham & Watkins advised the underwriters involved. CureVac N.V. announced the pricing of 27,027,028 common shares...
ADC Therapeutics’s $60 Million Common Shares Secondary Offering
Davis Polk and Homburger advised ADC Therapeutics, while Cooley and Lenz & Staehelin advised the underwriter. ADC Therapeutics SA announced a registered secondary offering of 12,000,000...
Roivant Sciences’ $230 Million Common Shares Offering
Davis Polk & Wardwell represented Roivant Sciences, while Latham & Watkins represented the underwriters in the offering. Roivant Sciences (Nasdaq: ROIV) has announced its $230 million...
Pacific Biosciences’ $201.25 Million Stock Offering
Wilson Sonsini advised Pacific Biosciences of California on the offering, and Davis Polk advised the representatives of the several underwriters involved. Pacific Biosciences of California Inc. announced...
Precigen’s $75 Million Common Stock Offering
Davis Polk and Hogan Lovells advised Precigen on the offering, and Goodwin Procter advised the underwriters involved. Precigen Inc. announced the SEC-registered offering of an aggregate of...
Deciphera Pharmaceuticals’ $135.1 Million Common Stock Offering
Goodwin Procter advised Deciphera Pharmaceuticals, and Davis Polk advised the joint book-running managers involved in the offering. Deciphera Pharmaceuticals Inc. announced a $135.1 million SEC-registered common stock...
Sun Pharmaceutical’s $576 Million Acquisition of Concert Pharmaceuticals
Davis Polk advised Sun Pharmaceutical, and Goodwin Procter advised Concert Pharmaceuticals. Sun Pharmaceutical Industries Limited announced its acquisition of Concert Pharmaceuticals Inc., through a tender offer for an...